Insulin is a cornerstone of type 1 diabetes mellitus (DM) treatment and is increasingly introduced early in the treatment course for patients with type 2 DM, who account for 90% to 95% of new DM cases annually.
1 During the last decade, the number of US patients with insulin-treated DM rose 50%; one-third of patients with diabetes currently use insulin,
2 and in 2012, insulin was estimated to cost the US health care system approximately $6 billion.
3 Tight glycemic control with insulin has been associated with reductions in disease complications among patients with type 1 DM
4 but has been increasingly associated with harms among patients with type 2 DM.
5-7 Insulin remains one of the most challenging and limiting aspects of DM medical management owing to complexities in dosing and administration, as well as the need for routine monitoring of blood glucose (BG) and food intake to avoid potentially fatal hypoglycemia.
8 The risk of insulin-related hypoglycemia is an important consideration when choosing among treatment options and individualizing glycemic targets, particularly in patients for whom benefits of intensive control are not as likely to be realized.
9,10